首页|乙酰半胱氨酸泡腾片联合双水平气道正压通气呼吸机治疗慢阻肺合并OSAHS患者的临床疗效探讨

乙酰半胱氨酸泡腾片联合双水平气道正压通气呼吸机治疗慢阻肺合并OSAHS患者的临床疗效探讨

扫码查看
目的 探究乙酰半胱氨酸泡腾片联合双水平气道正压通气(BiPAP)呼吸机对慢性阻塞性肺疾病(慢阻肺,COPD)合并阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者的治疗效果.方法 选择 71 例COPD合并OSAHS患者作为研究对象,将其随机分为观察组(36 例)与对照组(35 例).对照组患者通过BiPAP呼吸机治疗,观察组患者则实施乙酰半胱氨酸泡腾片联合BiPAP呼吸机治疗.比较两组患者临床疗效、肺功能指标[第 1 秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]、血气分析[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)]、呼吸暂停低通气指数(AHI)、炎症相关指标[白细胞介素-6(IL-6)、C反应蛋白(CRP)、降钙素原(PCT)].结果 观察组患者总有效率为 88.89%,显著高于对照组的 65.71%(P<0.05).观察组患者FEV1(2.03±0.34)L、FVC(2.86±0.11)L、FEV1/FVC(83.17±4.85)%均明显高于对照组的(1.72±0.27)L、(2.13±0.36)L、(67.27±3.56)%(P<0.05).观察组患者PaO2(89.52±4.75)mm Hg(1 mm Hg=0.133 kPa)、PaCO2(41.35±2.03)mm Hg及AHI(10.86±1.48)次/h均优于对照组的(80.37±4.54)mm Hg、(43.36±3.55)mm Hg、(35.25±5.50)次/h(P<0.05).观察组患者IL-6(9.62±1.45)pg/ml、CRP(13.15±2.47)mg/L、PCT(0.05±0.08)ng/ml均明显低于对照组的(18.13±3.21)pg/ml、(22.32±4.28)mg/L、(0.08±0.02)ng/ml(P<0.05).结论 乙酰半胱氨酸泡腾片与BiPAP呼吸机联合治疗COPD合并OSAHS患者的疗效好,值得推广.
Exploring the clinical efficacy of acetylcysteine effervescent tablets combined with bi-level positive airway pressure ventilator in the treatment of patients with chronic obstructive pulmonary disease complicated with OSAHS
Objective To explore the effect of acetylcysteine effervescent tablets combined with bi-level positive airway pressure(BiPAP)ventilator in the treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with obstructive sleep apnea-hypopnea syndrome(OSAHS).Methods 71 patients with COPD complicated with OSAHS were selected as the study subjects.They were randomly divided into an observation group(36 cases)and a control group(35 cases).Patients in the control group were treated with BiPAP ventilator,those in the observation group were treated with a combination of acetylcysteine effervescent tablets and BiPAP ventilator.Patients in both groups were compared in terms of clinical efficacy,pulmonary function indicators[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC],blood gas analysis[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)],apnea hypopnea index(AHI),inflammation related indicators[interleukin-6(IL-6),C-reactive protein(CRP),procalcitonin(PCT)].Results The total effective rate of 88.89%in the observation group was significantly higher than 65.71%in the control group(P<0.05).The observation group had FEV1 of(2.03±0.34)L,FVC of(2.86±0.11)L,and FEV1/FVC of(83.17±4.85)%,which were significantly higher than(1.72±0.27)L,(2.13±0.36)L,and(67.27±3.56)%in the control group(P<0.05).The observation group had PaO2 of(89.52±4.75)mm Hg(1 mm Hg=0.133 kPa),PaCO2 of(41.35±2.03)mm Hg and AHI of(10.86±1.48)times/h,which were better than(80.37±4.54)mm Hg,(43.36±3.55)mm Hg and(35.25±5.50)times/h in the control group(P<0.05).The observation group had IL-6 of(9.62±1.45)pg/ml,CRP of(13.15±2.47)mg/L and PCT of(0.05±0.08)ng/ml,which were significantly lower than(18.13±3.21)pg/ml,(22.32±4.28)mg/L and(0.08±0.02)ng/ml in the control group(P<0.05).Conclusion The combination of acetylcysteine effervescent tablets and BiPAP ventilator is highly effective in the treatment of patients with COPD and OSAHS,and is worthy of promotion.

Acetylcysteine effervescent tabletsBi-level positive airway pressure ventilationChronic obstructive pulmonary diseaseObstructive sleep apnea-hypopnea syndrome

张兰

展开 >

250000 济南市第七人民医院呼吸内科

乙酰半胱氨酸泡腾片 双水平气道正压通气呼吸机 慢性阻塞性肺疾病 阻塞性睡眠呼吸暂停低通气综合征

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(19)